Browse through our press and news section by category:

07.12.2012, SCHOTT AG, Moscow (Russia)

Pharmtech 2012: SCHOTT underlines strong position in Russian pharmaceutical market

Profound knowledge of GMP a key factor in customers’ success and the government’s Pharma 2020 strategy
Moscow, November 9, 2012 – SCHOTT will be presenting its latest products in the area of high-quality primary pharmaceutical packaging and sharing key innovations with industry representatives at the “Pharmtech 2012” exhibition in Moscow. The main products on display at the SCHOTT booth will include the company’s latest innovations in the area of vials and prefillable syringes. “By offering products of consistently high quality that meet the highest standards and customer requirements on the way to implementing GMP, SCHOTT is actively supporting modernization of the industry in terms of the Pharma 2020 state strategy,” says Ruediger Wagner, Regional Sales Manager for SCHOTT Russia and CIS. The Pharmtech 2012 exhibition takes place from November 26 to 29 in Moscow. SCHOTT will be exhibiting at Pavilion 75, Booth B111. The exhibition will also include a business forum for the pharmaceutical industry. Here, SCHOTT’s experts Christian Helbig and Sergey Sokolov will be discussing the company’s latest solutions in the area of prefillable glass and polymer syringes (November 28 at 3:05 p.m.).

High quality production according to GMP standards (Good Manufacturing Practice) is currently an important topic to the Russian pharmaceutical industry. SCHOTT is one of the few manufacturers whose local production is already fully compliant to this standard that will be compulsory in Russia from 2014. The company’s plant in Zavolzhe has been in operation now for one and a half years and SCHOTT has managed to extend its customer base quite significantly as a result of its local presence and GMP knowledge. In fact, the company has already shipped far more than 150 million high-quality ampoules and vials for use in the Russian and CIS markets. Prior to opening the plant, 50% of the high-quality ampoules and all of the premium quality vials had to be imported. Today, however, SCHOTT’s customers benefit from shorter distances, costs savings, support in their own local language, and products of international quality.

SCHOTT’s product highlights at Pharmtech 2012 With Type I plus®, SCHOTT introduced a set of delamination resistant vials for the first time ever. SCHOTT Type I plus® vials are particularly well-suited for pharmaceutical products that are incapable of being stored in conventional Type I glass. These include biopharmaceutical proteins, for example, which tend to show denaturation or formulations that interact with their containers. SCHOTT Type I plus® features a coating on the inside that is covalently bonded with the glass matrix and drastically reduces interactions between the glass surface and the respective medication. This translates into greater security and higher stability for medications. The vials with their outstanding barrier properties can be subjected to all types of normal pharmaceutical procedures, including washing, autoclaving, sterilization or depyrogenation.

Syringes from SCHOTT are used for a broad range of parenteral drugs in the pharmaceutical, cosmetics and biotech industries. SCHOTT offers a wide selection of syringe systems made of glass and polymer to meet all market requirements. SCHOTT forma 3s® glass syringes, for instance, are produced from high-quality SCHOTT Fiolax® Type I glass tubing on fully automated production lines. The products are available with a glued/staked-in needle, a Luer cone or a Luer-Lock adapter in sizes of between 0.5 and 3 milliliters. The syringes are washed, siliconized and assembled with a TipCap or needle shield and supplied to pharmaceutical companies in sterilized nest and tub configuration for aseptic filling.

The prefillable SCHOTT TopPac® polymer syringes, on the other hand, are manufactured out of COC (Cyclo-Olefin-Copolymer). SCHOTT TopPac® syringes are break resistant, light and transparent, and offer excellent barrier properties compared to other polymers used in the industry. They are also supplied in a nest and tub configuration and can be used directly for aseptic filling. Furthermore, they release no ions or heavy metals and the particle level is lower than that of glass syringes. SCHOTT TopPac® syringes are available in the range of 1 ml to 50 ml with an integrated Luer-Lock that offers a robust system and “ease of use” for end users.

About SCHOTT Pharmaceutical Systems
SCHOTT Pharmaceutical Systems is one of the world’s leading suppliers of glass tubing and primary packaging for the pharmaceutical industry. We provide our customers with quality solutions while meeting their highest demands with our material expertise, specialized analytical lab services, and a broad product portfolio, including syringes, cartridges, vials, ampoules, and special articles made of glass and COC polymer. With five glass tubing production sites and fifteen sites for pharmaceutical packaging spread over four continents, we are a reliable supplier that offers local service. Our state-of-the-art production facilities and products comply with the highest international quality standards for pharmaceutical needs.

About SCHOTT
SCHOTT is an international technology group with more than 125 years of experience in the areas of specialty glasses and materials and advanced technologies. SCHOTT ranks number one in the world with many of its products. Its core markets are the household appliance, solar power, pharmaceuticals, electronics, optics, transportation and architecture industries. The company is strongly committed to contributing to its customers’ success and making SCHOTT an important part of people’s lives with high-quality products and intelligent solutions. SCHOTT is committed to managing its business in a sustainable manner and supporting its employees, society and the environment. The SCHOTT Group maintains close proximity to its customers with manufacturing and sales units in all major markets. Its workforce of around 17,000 employees generated worldwide sales of approximately 2.9 billion euros for the 2010/2011 fiscal year. SCHOTT AG, with its headquarters in Mainz (Germany) is owned by the Carl Zeiss Foundation.

Media contacts:
SCHOTT AG
Christina Rettig
PR Manager
Phone: +49 (0)6131 - 66 4094
Fax: +49 (0)3641 - 28889 141
christina.rettig@schott.com
www.schott.com


PRP Group:
Maria Skvortsova
Phone:. +7 (495) 937-3170
schott@prp.ru
Press contact
SCHOTT AG
Christina Rettig
PR Manager
Phone: +49 (0)6131 - 66 4094
Fax: +49 (0)3641 - 28889 141
SCHOTT uses Cookies on this Website to enhance the user experience and provide the best possible Service. By continuing to browse the Website, you consent to our use of Cookies.